Загрузка...
Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both preclinical and clinical testing, necessitating...
Сохранить в:
| Опубликовано в: : | Front Oncol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6928193/ https://ncbi.nlm.nih.gov/pubmed/31921673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01416 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|